Article

A Prospective Observational Study on Pain Management in Cancer Patients and Telephonic Assessment of Nausea and Vomiting

Author : Dr. Sravanthi Jookanti, Dr. Mohammed Moizuddin, Dr. Shaik Faqera, Dr. T. Supriya, Dr. K. Krishnamani, Dr. A. V. Kishore Babu.

Background: Chemotherapy of cancer has many side effects. Nausea and Vomiting happen to be one of the most common side effects of chemotherapy in cancer patients. One of the most common symptoms seen in cancer patients is pain. It may limit the efficacy of work in daily life activities of the patient. Pain is defined as a highly unpleasant physical sensation caused by “illness or injury”. Nausea is the sensation of being about to vomit. Vomiting or emesis is the expelling of undigested food through the mouth. Aim: The aim of this study is to evaluate the pain management in cancer patients and telephonic assessment of nausea and vomiting. Methodology: This study was conducted with the objective to assess the pain, to evaluate the management of pain in cancer patients, to evaluate the incidence of nausea and vomiting through questionnaires via Telephone, in Care hospitals, Hi- Tech city, Hyderabad. This study is observational in nature and the subjects enrolled under this study were about 116. Informed consent was obtained from all the subjects. Subjects recruited in this study were admitted as in patients in the hospital to receive chemotherapy. The assessment of pain is done by using Visual analogue scale. Results: In this study, a total of 116 subjects with cancer were evaluated. Out of 116 subjects 109 subjects (93.9%) had mild pain and 07(6.03%) subjects were having moderate pain. For 69 subjects (59.4%) Tramadol was given, for 41 subjects (35.3%) Tab. Ultracet was given and for 06 subjects (5.17%) Morphine was given. 12 subjects (10.3%) had nausea, 5 subjects (4.31%) had vomiting, 3 subjects (2.5%) had both nausea and vomiting. Whereas 96 subjects (82.7%) had no incidence of nausea and vomiting. In most of the subjects there was no incidence of Nausea and Vomiting, as they were administered with Pre-medications during chemotherapy cycle and during discharge, 74 subjects (63.06) were prescribed with Tab. Zofer, 42 subjects (36.2%) were prescribed with Tab. Domstal. Conclusion: A total of 116 patients were observed who are undergoing chemotherapy. Among them mild pain is dominant with 109(93.9%) subjects, 59.4% of subjects were receiving Tramadol for pain management. Absence of nausea and vomiting is prominent with 96 subjects (82.75) as they were administered with pre medications during chemotherapy as prophylaxis for nausea and vomiting. Zofer is prominent as it is prescribed as discharge medication after chemotherapy with 72(62.75%) subjects. Out of which, 109(93.95) subjects are independent of others to perform their daily activities.


Full Text Attachment

Abstracted and Indexed In